An interventional study of Standard Multidisciplinary Treatment and Digital Monitoring Tool in Substance-related Disorders, sponsored by Clínica Nuestra Señora de la Paz. Recruiting at 2 sites in Spain. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-05-14.
Sponsored by Clínica Nuestra Señora de la Paz · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Substance-Related Disorders with a site in Spain — 6 open to participants now, 7 under way, none of them phase 3. Substance-Related Disorders · Spain.
Among the 26 studies in Substance-Related Disorders with a site in Spain, this one is the 8th largest by planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2026, is one of 17 with no phase, and was the 25th registered.
2,242 studies on the registry are indexed under Substance-Related Disorders; 408 are open to participants now.
Browse Substance-Related Disorders studies →6 of the 26 studies in Substance-Related Disorders with a site in Spain are open now. Recruiting first, the newest first:
Hospital Virgen del Puerto · Sites in Spain
Ages 18+
NORCE Norwegian Research Centre AS · Sites in Spain, Austria, Israel and 5 more countries
Ages 18+
University of Huelva · Sites in Spain
Ages 18+
University of Santiago de Compostela · Sites in Spain
Ages 40+ · Healthy volunteers
University of Valencia · Sites in Spain
Ages 18+ · Men only
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 266 Substance-Related Disorders studies recruiting now, 130 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 90 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 150 is above the median of 108 across 1,844 interventional studies indexed under Substance-Related Disorders.
Median enrollment 131 across the 20 interventional studies, 403 across the 6 observational. Of the 12 that completed or were terminated, 1 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 26 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Clínica Nuestra Señora de la Paz as lead sponsor.
Clínica Nuestra Señora de la Paz has 1 study filed under Substance-Related Disorders — fewer than ten, so there is no comparison to draw.
2 of the studies in Substance-Related Disorders with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07052175Clínica Nuestra Señora de la PazPrevention of Relapse in Behavioral Disorders | 2026-12 |
| NCT07443033Hospital Virgen del PuertoPsychosocial Factors in Dual Diagnosis in a General Hospital | 2027-04-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 26 studies in Substance-Related Disorders with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to validate the effectiveness of a digital tool for monitoring and early relapse detection in addiction treatment. It compares outcomes between a traditional multidisciplinary model and the same model enhanced by the technology. The research seeks to demonstrate the tool's added clinical value in improving long-term recovery outcomes.
The primary objective of this research project is to scientifically validate the effectiveness of a technological tool for monitoring and early detection of relapse in addiction treatment. The study will focus on comparing two approaches: the traditional comprehensive multidisciplinary treatment model and the same model enhanced by the integration of a digital technology.
The comprehensive model addresses the biological, psychological, and social dimensions of substance use disorders through a structured sequence of phases: initial assessment, detoxification, withdrawal management, rehabilitation, social reintegration, and follow-up care. The core innovation of this study lies in the implementation of a digital application specifically designed to monitor patients' clinical status, detect early warning signs of relapse, and deliver timely, personalized interventions.
A longitudinal quasi-experimental study will be conducted with a sample of 150 individuals diagnosed with substance use disorders (including alcohol, cocaine, and other stimulants). Validated assessment instruments will be used to evaluate clinical progress, comparing outcomes between patients receiving standard treatment and those receiving the same treatment augmented by the digital tool.
Key outcome variables include reduction in withdrawal symptoms, decrease in craving, improvement in emotional well-being and psychosocial functioning, relapse rates, and patient satisfaction. In addition, the feasibility, acceptability, and clinical utility of the technological tool in therapeutic follow-up will be assessed.
The study is expected to provide empirical evidence on the added value of the digital tool in addiction treatment, with the aim of optimizing existing clinical protocols and enhancing the long-term effectiveness of intervention strategies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group will receive the standard multidisciplinary treatment for substance use disorders, including clinical evaluation, medical detoxification, psychological and psychiatric therapy, occupational rehabilitation, and social reintegration, without the use of the digital tool
Behavioral: Standard Multidisciplinary Treatment
Participants in this group will receive the same standard multidisciplinary treatment as Arm 1, complemented by a digital tool designed for real-time monitoring, early relapse detection, and personalized feedback throughout the follow-up phase
Behavioral: Standard Multidisciplinary Treatment · Behavioral: Digital Monitoring Tool
Comprehensive intervention including structured phases: initial assessment, detoxification, withdrawal management, psychological and psychiatric therapy, rehabilitation, and follow-up care. Delivered by a multidisciplinary team according to established clinical protocols.
In addition to standard care, participants will use a mobile application that monitors clinical indicators, detects early signs of relapse risk, and provides personalized alerts and intervention prompts. The tool is designed to support both patients and clinicians in decision-making and therapeutic follow-up.
Biological Verification of Substance Use Relapse via Toxicological Testing: Urinalysis
To objectively identify episodes of relapse (e.g., alcohol or other substance use) during treatment, periodic toxicological screenings will be performed as part of the therapeutic monitoring process. These screenings are conducted by clinical personnel and include urinalysis: detection of recent use of psychoactive substances through urine samples, providing an objective measure of treatment adherence.
Time frame: Throughout the intervention and follow-up phases (baseline to 12 months)
Biological Verification of Substance Use Relapse via Toxicological Testing: Breath Alcohol Testing
To objectively identify episodes of alcohol relapse during treatment, periodic toxicological screenings will be conducted as part of the therapeutic monitoring process. These screenings will be carried out by clinical staff and will include Breath Alcohol Testing: measurement of breath alcohol concentration using spirometry-based devices to detect recent alcohol consumption.
Time frame: Throughout the intervention and follow-up phases (baseline to 12 months)
WHOQOL-BREF
A 26-item instrument assessing perceived quality of life across four domains: physical health, psychological well-being, social relationships, and environmental context. Items are rated on a 5-point Likert scale, and domain scores are transformed to a 0-100 scale. Demonstrates good internal consistency, with Cronbach's alpha ranging from 0.69 (physical) to 0.90 (spirituality/religion/personal beliefs).
Time frame: Baseline, post-treatment (3 months), and follow-up (6 and 12 months)
Purpose in Life Test - Short Form (PIL-10)
A 10-item self-report scale assessing life purpose and personal meaning, adapted from the original PIL (Crumbaugh \& Maholick, 1969). Responses are rated on a 7-point Likert scale, with total scores ranging from 10 to 70. Higher scores reflect greater perceived purpose. The scale includes two dimensions: (a) life satisfaction and meaning, and (b) goals and direction. Shows good psychometric properties (α = .85 overall; .84 for life satisfaction and .69 for goals and purpose).
Time frame: Baseline, post-treatment (3 months), and follow-up (6 and 12 months)
Patient Health Questionnaire-9 (PHQ-9)
A 9-item self-report tool assessing depressive symptom severity over the past two weeks, based on DSM-IV criteria. Each item is scored from 0 (not at all) to 3 (nearly every day), yielding a total score of 0-27. A cut-off score of 10 yields sensitivity of 0.78 and specificity of 0.87. Spanish versions show excellent reliability (α = 0.78-0.90), with current data showing α = .93.
Time frame: Baseline, post-treatment (3 months), and follow-up (6 and 12 months)
Beliefs About Substance Use and Craving Beliefs Questionnaire
25 items self-report questionnaire designed to assess maladaptive beliefs related to substance use and beliefs about substance craving. Each item is rated on a 5-point Likert scale ranging from "totally disagree" to "totally agree". Higher total scores reflect stronger dysfunctional beliefs associated with substance use (e.g., perceived benefits or inevitability of use). The instrument shows excellent internal consistency (Cronbach's alpha = 0.87).
Time frame: Baseline, post-treatment (3 months), and follow-up (6 and 12 months)
Patient Satisfaction with the Digital Application
27-item ad hoc questionnaire using a 5-point Likert scale (scale from 1 to 5, with 1 being "Not at all" and 5 being "Very much") to assess patient satisfaction with the application's usability, safety, and overall experience. Higher scores indicate greater satisfaction.
Time frame: Post-treatment (3 months)
Plan to share: No — IPD information will not be shared due to the sensitivity of the data it contains, which could allow for the direct or indirect identification of patients.
Started Apr 2026 (actual). Primary completion is estimated for Dec 2026, 8 months after the start.
Of 819 non-industry interventional studies with no phase under Substance-Related Disorders, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 53. This study's planned 8 months is below that.
Counting every sponsor, half of 859 studies reached it within 34 months; a quarter within 17 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.